Prima, AstraZeneca deal

AZN and PRR's Arthron Pty Ltd. subsidiary extended to June 30, 2006, their 2004 deal to study Arthron's Fc receptor technology. PRR said the Fc gamma receptor IIa (CD32) is a target for autoimmune di...